Press release
The novel ocular drug delivery devices market is projected to grow at a CAGR of 15%, till 2030, claims Roots Analysis
Roots Analysis has announced the addition of the “Novel Ocular Drug Delivery Devices Market, 2021 – 2030” report to its list of offerings.
Over the years, a number of companies have developed several novel and advanced drug delivery devices, which are reported to be capable of addressing the known challenges in this domain. The anticipated growth in the patient population for such disorders is likely to increase demand for effective and patient centric ocular drug delivery devices.
To order this 200+ page report, which features 90+ figures and 115+ tables, please visit this https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.html
Key Market Insights
Over 45 novel ocular drug delivery devices have either been approved or are being developed
Currently, 13% of such drug delivery devices are marketed, while majority (44%) of the systems are being evaluated in preclinical and discovery stages. Further, most (88%) of these devices are intended for the delivery of small molecule-based therapies.
Close to 80% of the novel ocular drug delivery devices in the pipeline are implants
Inserts and punctal plugs represent 10% of the development pipeline, each. Further, majority (60%) of such drug delivery devices are biodegradable. It is also worth mentioning that most (75%) of the ocular drug delivery device developers are based in North America, primarily in the US.
Clinical trials registered in this domain have increased at a CAGR of 29%, during 2018-2021
A number of clinical studies focused on the evaluation of novel drug delivery devices are currently ongoing worldwide. Of the total, close to 55% of the studies have already been completed, followed by 33% trials which are currently active and recruiting patients.
Over 1,145 patents related to novel ocular drug delivery devices have been granted / filed
There was significant increase in the number of patent applications filed over the last few years. Interestingly, more than 100 patents were filed / granted in 2020. Further, around 45% of the patents were filed in North America. It is worth highlighting that most of the patents were granted / filed for ocular implants.
Partnership activity within this domain has increased at a CAGR of 18%, between 2017 and 2021
Research and development agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product commercialization agreements (12%), product commercialization and development agreements (12%), and product distribution agreements (8%).
More than USD 3.5 billion has been invested by both private and public investors in this domain
It is important to mention that, between pre-2011 and 2021, majority of the funding amount was raised through secondary offerings (68%) and debt financing (20%). Further, most (93%) of the funding rounds were reported in the US.
North America and Europe are anticipated to capture over 88% of the market share, by 2030
The current market is driven by sales of novel ocular drug delivery devices designed to treat non-infectious uveitis (over 32%), followed by those targeting diabetic macular edema (22%) and glaucoma (13%). Further, ocular drug delivery inserts currently capture the dominant share (90%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future.
To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market/request-sample.html
Key Questions Answered
Who are the leading novel ocular drug delivery device developers?
Which are the popular types of novel ocular drug delivery devices available in this market?
What are the key challenges faced by stakeholders engaged in this domain?
What types of partnership models are commonly being adopted by stakeholders in this industry?
Who are the key investors in this domain?
How is the intellectual property landscape in this field likely to evolve in the foreseen future?
What are the factors that are likely to influence the evolution of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the novel ocular drug delivery devices market has been analyzed across the following segments:
Type of Drug Delivery Device
Implant
Insert
Punctal Plugs
Target Indication
Glaucoma
Retinal vein occlusion
Postoperative ocular inflammation
Non-infectious uveitis
Diabetic macular edema
Dry eye disease
Wet age-related macular degeneration
Retinal diseases
Neovascular age-related macular degeneration
Others
Type of Product
Biodegradable
Non-biodegradable
Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World
The report includes profiles of key players (listed below); each profile features an overview of the company, details related to its financials (if available), technology overview, product portfolios, recent developments and an informed future outlook.
Alimera Sciences
Bausch & Lomb
EyePoint Pharmaceuticals
Genentech
Glaukos
Neurotech Pharmaceuticals
Ocular Therapeutix
For additional details, please visit
https://www.rootsanalysis.com/reports/novel-ocular-drug-delivery-devices-market.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. On-body Drug Delivery Devices Market, 2021-2030
2. Non-Viral Drug Delivery Systems Market, 2021-2030
3. Connected / Smart Drug Delivery Systems Market, 2021-2030
4. Diabetes Drug Delivery Devices Market, 2020-2030
5. Organ-based / Targeted Drug Delivery Devices Market, 2020-2030
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The novel ocular drug delivery devices market is projected to grow at a CAGR of 15%, till 2030, claims Roots Analysis here
News-ID: 2425172 • Views: …
More Releases from Roots Analysis
The Agricultural Biologicals Market Size Worth over USD 40 Billion in 2035 | Roo …
Global Agricultural Biologicals Market Overview
The agricultural biologicals market is a rapidly growing and dynamic industry that is poised to grow at a CAGR of 9.98% in the forecast period 2023-2035. The growth in the agricultural biologicals market size over the next decade is likely to be the result of a rise in the demand for organic food coupled with the growing focus on sustainable agriculture. Agricultural biologics include a vast…
The Lab Automation Market is anticipated to grow at a CAGR of around 15% by 2035 …
Owing to the advanced features and cost-saving potential of automation, stakeholders in the healthcare industry are adopting lab automation systems in order to get precise results and reduce deviations occurring due to manual handling
Roots Analysis has announced the addition of "Lab Automation Market, 2023-2035" report to its list of offerings.
The diverse applications of lab automation systems, including advanced data management, high reproducibility and increased productivity in the biotechnology…
The gene therapy market is projected to be worth USD 17.3 billion in 2035, growi …
Given the potential of gene therapies to permanently cure a diverse array of clinical conditions at the genetic level, the current pipeline is rapidly growing; a number of such therapies are currently being evaluated in late stages of development
London
Roots Analysis has announced the addition of "Gene Therapy Market" report to its list of offerings.
Post the emergence of blockbuster gene therapies, such as ZOLGENSMA® (for spinal muscular atrophy type…
The companion diagnostics development services market, is anticipated to grow at …
Roots Analysis has announced the addition of "Companion Diagnostics Development Services Market (2nd Edition), 2022-2035" report to its list of offerings.
The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
